LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
Category: #health  By Mateen Dalal  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition

LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acquired Everest Biotech, a certified expert in antigen polyclonal antibodies. The acquisition  will help LifeSpan BioSciences expand its product offering and strengthen its position as the fastest growing provider in the market for research reagent.

LSBio, though this partnership, will offer a comprehensive reagents catalogue which can be combined with the wide range of IHC validated primary antibodies.

Heather Holemon, LSBio’s CEO said that the company is looking forward to adding the product range produced by Everest Biotech to its portfolio. The offerings by Everest Biotech stand out owing to their exceptional high quality, which will perfectly complement LSBio’s existing portfolio.

Citing reliable sources, Everest Biotech is committed towards continuous improvement and quality that has ensured the growth of the company’s catalogue. It now has scores of goat antibodies against a wide range of mouse, rat and human targets in the biomedical space.

LSBio’s offering of more than 500,000 polyclonal and monoclonal primary antibodies will expand to include all protein in the proteome after the acquisition. Over 15,000 antibodies of LSBio have been identified as IHC reagents that are exceptional and have been given the IHC-plus brand through the extensive in-house testing.

Apparently, after LSBio acquired Nordic-MUbio in February, the Everest Bio acquisition will mark the second investment made by the company this year.

For the uninitiated, LifeSpan BioSciences, Inc. provides IHC validated reagent antibodies along with services to the global community of pharmaceutical, biotech and academic researchers and has been a leader in the industry after its inception in 1995.

The company has built a catalogue that contains over 750,000 antibodies, proteins, biochemicals and assay kits which it sells through the network of its international distributors.

 

Source Credit-https://finance.yahoo.com/news/lifespan-biosciences-announces-acquisition-everest-080000460.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
By Mateen Dalal

NantHealth, Inc., a personalized, evidence-based, next-generation healthcare company and NantOmics, LLC, one of the leading companies in molecular analysis, have reportedly launched an innovative AI platform for assisting pathologists in image-based ...

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...